Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: Clinical and economic impact

American Journal of Ophthalmology

Volumn 153, Issue 3, 2012, Pages 468-473.e1

  Shienbaum, Gary ^a   Gupta, Omesh P ^a   Fecarotta, Christopher ^a   Patel, Avni H ^a   Kaiser, Richard S ^a   Regillo, Carl D ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG COST; DRUG DOSE REGIMEN; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICARE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SLIT LAMP; SUBRETINAL FLUID; VISUAL ACUITY;

EID: 84857446008     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2011.08.011     Document Type: Article

References (24)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431 (Pubitemid 44511557)
2. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444 (Pubitemid 44511558)
3. R.F. Spaide, K. Laud, H.F. Fine Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 4 2006 383 390 (Pubitemid 44197628)
4. R.M. Rich, P.J. Rosenfeld, C.A. Puliafito Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 5 2006 495 511 (Pubitemid 44620390)
5. R.L. Avery, D.J. Pieramici, M.D. Rabena, A.A. Castellarin, M.A. Nasir, M.J. Giust Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 3 2006 363 372
6. M.V. Emerson, A.K. Lauer, C.J. Flaxel Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration Retina 27 4 2007 439 444 (Pubitemid 46624283)
7. Z.F. Bashshur, Z.A. Haddad, A.R. Schakal, R.F. Jaafar, A. Saad, B.N. Noureddin Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study Am J Ophthalmol 148 1 2009 59 65
8. J.F. Arevalo, J.G. Snchez, L. Wu Pan-American Collaborative Retina Study Group Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study Ophthalmology 117 10 2010 1974 1981
9. A. Tufail, P.J. Patel, C. Egan ABC Trial Investigators Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study BMJ 340 2010 c2459
10. The CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
11. A.E. Fung, G.A. Lalwani, P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 4 2007 566 583
12. I. Mantel, L. Zografos, A. Ambresin Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration Ophthalmologica 222 5 2008 321 323
13. L. Arias, J.M. Caminal, L. Casas A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Br J Ophthalmol 92 12 2008 1636 1641
14. S.Y. Cohen, L. Dubois, R. Tadayoni Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting Am J Ophthalmol 148 3 2009 409 413
15. H. Dadgostar, A.A. Ventura, J.Y. Chung, S. Sharma, P.K. Kaiser Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 9 2009 1740 1747
16. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 1 2009 43 58
17. O.P. Gupta, G. Shienbaum, A.H. Patel, C. Fecarotta, R.S. Kaiser, C.D. Regillo A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact Ophthalmology 117 11 2010 2134 2140
18. H. Oubraham, S.Y. Cohen, S. Samimi Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 1 2011 26 30
19. S.P. Rothenbuehler, D. Waeber, C.K. Brinkmann, S. Wolf, U.E. Wolf-Schnurrbusch Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration Am J Ophthalmol 147 5 2009 831 837
20. D.S. Boyer, J.S. Heier, D.M. Brown, S.F. Francom, T. Ianchulev, R.G. Rubio A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 9 2009 1731 1739
21. R. Spaide Ranibizumab according to need: a treatment for age-related macular degeneration Am J Ophthalmol 143 4 2007 679 680 (Pubitemid 46452536)
22. D.M. Brown, C.D. Regillo Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients Am J Ophthalmol 144 4 2007 627 637
23. M. Engelbert, S.A. Zweifel, K.B. Freund "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation Retina 29 10 2009 1424 1431
24. J. Sears, J. Bena, A.D. Singh CATT: into the eye of a tiger Br J Ophthalmol 95 6 2011 761